Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | F10 | P00742 | 5/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | OGG1 | O15527 | 1/20 | 0.68 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562057 | 0.89 | MAPT (0.72) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL14315172 | 0.88 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL23353224 | 0.88 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL29865475 | 0.88 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL16562249 | 0.88 | MAPT (0.76) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL14096502 | 0.86 | ALDH1A1 (0.72) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL6590758 | 0.85 | PRSS12 (0.76) | F10PRSS12 | |
| SCHEMBL6590786 | 0.85 | F10 (0.88) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL29865482 | 0.85 | MAPT (0.74) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL23353332 | 0.85 | MAPT (0.74) | MAPTSMN1; SMN2TP53RXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| US-7148259-B1 | Antibacterial agents | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-6780858-B2 | Antibacterial agents | TULARIK INC. | 2004-08-24 | — | — | US | disclosed |
| US-20020045749-A1 | Antibacterial agents | AMGEN INC. | 2002-04-18 | — | — | US | disclosed |
| US-5712304-A | MICROBIOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | MAPT 4113/4885SMN1; SMN2 3304/4885TP53 3878/4885 |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | MAPT 1802/4885SMN1; SMN2 2627/4885TP53 1149/4885 |
| US-20020045749-A1 | Antibacterial agents | MRPL21, HDHD5, CLPP | MAPT 4113/4885SMN1; SMN2 3304/4885TP53 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.